Procognia has been Granted an Additional Patent in Japan
This patent joins the company's 21 other patents that have been granted in the USA, the EU, Australia, Japan, and elsewhere
Procognia, which deals in the research, development, manufacture, and
Procognia, which deals in the research, development, manufacture, and sale of technological products for the bio-pharmaceutical and life sciences industries, announced today that it has been granted another substantial patent in Japan. This new patent covers the biological assay Procognia has developed for the analysis of the sugar structure of proteins and polysaccharides (glycoanalysis) using its lectin array (glycan-binding proteins) on glass slides.
This patent joins 21 additional patents Procognia has been granted in the USA, the EU, Australia, Japan, and other countries. These patents broadly protect the technology the company has developed and its various applications, including:
Use of the GlycoScopeTM product, an analytic tool mainly used by pharmaceutical companies.
Possible uses in the diagnosis of disease (by analyzing the structural changes of glycans in serum of cancer patients).
Use in the development of biological and biosimilar drugs to monitor changes in their glycan structure during the development of these drugs.
Use in the development of stem cell applications.
In addition, the patent also covers the usage of the company's technology in the food industry (for example, to identify counterfeit food).
Alon Natanson, President and CEO of Procognia, said: "The issuance of the patent in Japan is an additional cornerstone towards the commercialization of Procognia's technology. Japan is considered to be one of the leaders in the field of glycobiology research, and therefore the Japanese market is one of our most important target markets. I want to stress that, as a worldwide trend, after mapping the human genome and proteome (genomics and proteomics), the scientific community is evolving in the direction of glycomics research. This field holds huge scientific and commercial potential, and therefore Procognia, which has developed unique glycoanalysis technologies, views this issuance as a major step forward."